On Monday, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) opened lower -3.98% from the last session, before settling in for the closing price of $0.62. Price fluctuations for ADAP have ranged from $0.53 to $2.05 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 193.13% over the last five years. Company’s average yearly earnings per share was noted 71.06% at the time writing. With a float of $226.49 million, this company’s outstanding shares have now reached $255.70 million.
The firm has a total of 449 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.26%, operating margin of -28.14%, and the pretax margin is -28.42%.
Adaptimmune Therapeutics Plc ADR (ADAP) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 42.02%. The most recent insider transaction that took place on Jun 18 ’24, was worth 22,814. In this transaction Chief Commercial Officer of this company sold 24,531 shares at a rate of $0.93, taking the stock ownership to the 38,293 shares. Before that another transaction happened on Jan 17 ’24, when Company’s Chief Executive Officer sold 30,080 for $0.67, making the entire transaction worth $20,244. This insider now owns 44,848 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 71.06% per share during the next fiscal year.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Check out the current performance indicators for Adaptimmune Therapeutics Plc ADR (ADAP). In the past quarter, the stock posted a quick ratio of 3.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.08 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Analysing the last 5-days average volume posted by the [Adaptimmune Therapeutics Plc ADR, ADAP], we can find that recorded value of 1.61 million was lower than the volume posted last year of 1.89 million. As of the previous 9 days, the stock’s Stochastic %D was 52.24%. Additionally, its Average True Range was 0.05.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 7.98%, which indicates a significant decrease from 41.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.74% in the past 14 days, which was higher than the 77.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6657, while its 200-day Moving Average is $0.9798. Now, the first resistance to watch is $0.6251. This is followed by the second major resistance level at $0.6549. The third major resistance level sits at $0.6798. If the price goes on to break the first support level at $0.5704, it is likely to go to the next support level at $0.5455. Now, if the price goes above the second support level, the third support stands at $0.5157.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
There are currently 255,883K shares outstanding in the company with a market cap of 152.33 million. Presently, the company’s annual sales total 60,280 K according to its annual income of -113,870 K. Last quarter, the company’s sales amounted to 40,900 K and its income totaled -17,620 K.
